LIN7A: A Potential Drug Target and Biomarker for Diseases (G8825)

Target Name: LIN7A

NCBI ID: G8825

LIN7A

LIN7A: A Potential Drug Target and Biomarker for Diseases

LIN7A (VELI1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor family and is involved in the regulation of cell signaling processes. LIN7A has been identified as a potential drug target and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LIN7A protein is composed of 156 amino acid residues and has a calculated molecular weight of 19.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is also found in the placenta and testes. LIN7A is a glycoprotein and has a high glycophosphorylated status, which suggests that it is involved in signaling processes that require the presence of a phosphate group.

LIN7A has been shown to play a role in a variety of physiological processes in the body. For example, LIN7A has been shown to regulate the development and differentiation of T cells, which are a critical immune cell that play a key role in protecting the body against infection and disease. LIN7A has also been shown to regulate the production of antibodies, which are proteins that are produced by the immune system in response to the presence of foreign substances in the body.

In addition to its role in T-cell regulation, LIN7A has also been shown to be involved in the regulation of cell signaling processes in other tissues. For example, LIN7A has been shown to play a role in the regulation of cell proliferation and differentiation, as well as in the regulation of cell migration and the formation of tissues.

Due to its involvement in a variety of physiological processes, LIN7A has been identified as a potential drug target. Several studies have shown that LIN7A can be targeted by small molecules, including inhibitors of the protein's tyrosine kinase activity. These inhibitors have been shown to have a variety of different effects on the cell, including the inhibition of cell proliferation and the regulation of cellular signaling processes.

In addition to its potential as a drug target, LIN7A has also been shown to be a valuable biomarker for a variety of diseases. For example, LIN7A has been shown to be overexpressed in a variety of cancer tissues and has been used as a biomarker for the diagnosis and prognosis of cancer. Additionally, LIN7A has been shown to be overexpressed in neurodegenerative diseases, including Alzheimer's disease, and has been used as a potential biomarker for the diagnosis and progression of these diseases.

Overall, LIN7A is a protein that has been shown to play a critical role in a variety of physiological processes in the body. Its potential as a drug target and as a biomarker make it an attractive target for research into the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of LIN7A in cell signaling processes and its potential as a drug and biomarker.

Protein Name: Lin-7 Homolog A, Crumbs Cell Polarity Complex Component

Functions: Plays a role in establishing and maintaining the asymmetric distribution of channels and receptors at the plasma membrane of polarized cells. Forms membrane-associated multiprotein complexes that may regulate delivery and recycling of proteins to the correct membrane domains. The tripartite complex composed of LIN7 (LIN7A, LIN7B or LIN7C), CASK and APBA1 associates with the motor protein KIF17 to transport vesicles containing N-methyl-D-aspartate (NMDA) receptor subunit NR2B along microtubules (By similarity). This complex may have the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Ensures the proper localization of GRIN2B (subunit 2B of the NMDA receptor) to neuronal postsynaptic density and may function in localizing synaptic vesicles at synapses where it is recruited by beta-catenin and cadherin. Required to localize Kir2 channels, GABA transporter (SLC6A12) and EGFR/ERBB1, ERBB2, ERBB3 and ERBB4 to the basolateral membrane of epithelial cells

The "LIN7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIN7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets